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Timely detection of infectious agents is critical in early diagnosis and treatment of infectious diseases.
Conventional pathogen detectionmethods, such as enzyme linked immunosorbent assay (ELISA), culturing
or polymerase chain reaction (PCR) require long assay times, and complex and expensive instruments,
which are not adaptable to point-of-care (POC) needs at resource-constrained as well as primary care
settings. Therefore, there is an unmet need to develop simple, rapid, and accurate methods for detection of
pathogens at the POC. Here, we present a portable, multiplex, inexpensive microfluidic-integrated surface
plasmon resonance (SPR) platform that detects and quantifies bacteria, i.e., Escherichia coli (E. coli) and
Staphylococcus aureus (S. aureus) rapidly. The platform presented reliable capture and detection of E. coli at
concentrations ranging from,105 to 3.23 107 CFUs/mL in phosphate buffered saline (PBS) and peritoneal
dialysis (PD) fluid. Themultiplexing and specificity capability of the platform was also tested with S. aureus
samples. The presented platform technology could potentially be applicable to capture and detect other
pathogens at the POC and primary care settings.
E
merging micro- and nano-scale bioengineering and biomedical technologies have provided broad applica-
tions (e.g., medical diagnostics and biosensors) in health sciences. Developing such platforms that are
affordable and rapid for infectious diseases is one of the top priorities for improving human health at
the point-of-care (POC) settings1–4. Currently, the standard testing for pathogen detection and quantification are
based on cell culture methods, which take 48 to 72 hours5–7. Other detection methods such as polymerase chain
reaction (PCR) and enzyme linked immunosorbent assay (ELISA), have been widely used to detect and quantify
pathogens with high sensitivity and specificity8. However, they require expensive equipment and well-trained
operators. Additionally, these assays are technically complex and need labor-intensive processing steps. Thus,
rapid and inexpensive diagnostic methods are needed that will eliminate peripheral instrumentation and allow to
deploy them to the POC. With the ongoing miniaturization in electronics, emerging technologies could allow
portable instruments and minimize the need for bulky laboratory infrastructure at the POC and primary care
settings9. Such self-contained and robust diagnostic devices could also lead to developing strategies for disease
monitoring and management10.
Microfluidics, being at the convergence of micro/nanoscale engineering, materials science, and biology enables
medical solutions for infectious disease diagnostics and monitoring11. Microfluidic technologies have been used
to manipulate microliter sample volumes and minimize reagent costs in several applications including cryobio-
logy, genetic and proteomic analysis controlling cancer microenvironment, and cell capture and cell release
studies11–17. In particular, analysis of bioagents (e.g., pathogens and infectious agents) is possible withmicrofluidic
technologies. For instance, capture and detection of intact viruses on microchips have been demonstrated18.
Microfluidic based diagnostic technologies have various characteristics, such as inexpensive fabrication, adapt-
ability and rapid results19–21. Integrating microfluidic platforms with optical imaging systems combines the
advantages of lab-chip platforms with the benefits of optical technologies22,23. In particular, photonics and
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plasmonics, e.g., surface plasmon resonance (SPR), localized surface
plasmon resonance (LSPR) and nanostructured photonic crystals,
being at the intersection of nanotechnology and optics, can be used
for developing reliable, accurate, easy-to-use biosensor plat-
forms24–28. Plasmonic lab-chip devices could be constructed as
affordable platforms by utilizing single-use, disposable microchips
for POC testing. In addition, disease specificity could be attained by
using various surface functionalization techniques. In plasmonic
sensor technologies, for instance SPR platforms, a biomolecular
recognition element is immobilized on metal surfaces (e.g., gold,
silver) for efficient, specific and selective capture of bioagents. The
limit of detection of SPR-based detection systems are affected by
factors including the target immobilization method (by affecting
the affinity), sample volume and transport properties (by affecting
the probability of capturing the target), the refractive index of the
target, and practical device parameters25,29,30. Microfluidics helps to
handle small sample volumes that affects overall sensor performance
and capture kinetics31.
Here, we present such a microfluidic-based SPR technology. We
validated this portable platform with Escherichia coli (E. coli) and
Staphylococcus aureus (S. aureus) spiked samples as a model patho-
gen detection system. Disposable microfluidic chips with gold coated
surfaces were functionalized with antibodies for efficient, selective
and specific capture of E. coli and S. aureus. We quantified the cap-
tured E. coli with brightfield and fluorescence imaging, and analyzed
the capture distribution spatially along the microchannels. Limit of
detection of the platform was evaluated, and standard curves were
generated for E. coli spiked in phosphate buffered saline (PBS) and
peritoneal dialysis (PD) fluid. Multiplexing and selectivity capability
was also assessed with S. aureus spiked in PBS samples.
Methods
Design and fabrication of microfluidic chips. The microfluidic chip design
comprises a single microchannel with an inlet and an outlet port. The microchip with
dimensions 31 mm 3 57 mm 3 7 mm was constructed as a cartridge for the
platform. Two PMMA (poly methyl methacrylate) (3.0 mm thick; McMaster Carr,
Atlanta, GA) layers were assembled using a layer of double sided adhesive (DSA,
50 mm thick; iTapestore, Scotch Plains, NJ). A second DSA layer (50 mm thick) and a
gold coated substrate formed the microchannel. The microchannel (12 mm 3 7 mm
3 50 mm) was located in the center of the microchip. The PMMA-DSA-PMMA-
DSA-gold chip was assembled as a single use, disposable microchip (Figure 1 and S1).
To fabricate the chip, the PMMA and DSA were cut using a laser cutter (Versa
LaserTM, Scottsdale, AZ). The two PMMA layers were assembled with a layer of DSA.
Two openings were cut on the PMMA layer (0.7 mm diameter) that formed the inlet
and outlet ports. The distance between these ports was 9 mm. The port openings with
diameters of 1.4 mm in DSA allowed fluid transfer without interruption. A second
DSA layer formed a microchannel in the center of the microchip with a channel
volume of 4 mL. The design of themicrochannel included sharp-edged ends. Finally, a
gold chip of dimensions 1.4 cm 3 1.4 cm was mounted onto the microchip. The
microchip design allows future extension of functionality, for instance by
incorporating a filter to isolate cells, such as white or red blood cells as shown before32.
Design and fabrication of gold coated glass surfaces. To realize disposable
microfluidic chips, glass wafers (Borofloat, Double Side Polished, diameter 5
100 mm, t 5 0.5 mm) were purchased from University Wafer, Boston, MA (Item
517), and were cleaned with acetone and isopropyl alcohol on the spinner cleaning
instrument (Headway PWM-32 Spinner). Then, the wafers were loaded on the
sample holders of an electron beam depositor (Denton E-beam Evaporator) for metal
deposition. The systemwas operated at 1027 Torr, and the wafers were deposited with
5 nm of titanium, followed by a 50 nm deposition of gold on a single side.
Subsequently, the metal coated wafers were spin coated with a , 0.5 mm layer of
S1805 photoresist (Shipley 1800-series photoresist) to protect the surface of the gold
layer from environmental effects. The spinner was run at 4000 rpm for 40 seconds,
and later, baked at 115uC on a hot-plate for 2 minutes. The wafers were cut in 1.4 cm
3 1.4 cm square chips using a mechanical dicer (DISCO DAD321 Dicing Saw) and
stored after cleaning with distilled water. Before microfluidic chip fabrication, the
gold chips were cleaned with solvents to remove any organic residues from the
fabrication process. In a solvent bench, chips were placed in an acetone bath and
Figure 1 | Portable plasmonic platform for pathogen detection and quantification. (a) The surface activated disposable microfluidic chips were
mounted on the top side of the device. The microchip with the inlet and outlet ports, and the 50 nm thick gold coated glass substrate along with the
disposable microchip is shown below. (b) The electronic setup of the device is represented from bottom. A light emitting diode illuminates a cylindrical
lens, which collimates the light onto a rectangular prism. The reflected light is captured by a CMOS sensor, and the image is transferred to a portable
computer using the control circuitry. The microfluidic chip is placed on the rectangular prism, with an refractive index matching oil in between. (c)
Schematics of the microfluidic integrated SPR platform. The gold surfaces were modified with several activators (i.e., 11-Mercaptoundeconoic Acid
(MUA), N - (3 - Dimethylaminopropyl) – N9 -ethylcarbodiimide Hydrochloride (EDC), N-Hydroxysuccinimide (NHS) and with anti-
Lipopolysaccharide (LPS) antibody to capture the E. coli. The bacteria are captured by the antibodies in themicrochannel, and the capture event induces a
change in the local refractive index. This change provides a signature on the reflected light, which is captured by the sensor and transferred to a computer
for analysis.
www.nature.com/scientificreports
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sonicated for 5 minutes. Then, they were transferred to a methanol bath and
sonicated for 5 minutes again. Finally, chips were transferred to an isopropanol bath
and gently shaken for final cleaning. The gold chips were then dried with nitrogen gas
to be used in the fabrication of the microfluidic chips.
E. coli culture and quantification. To analyze and visualize the bacteria distribution
on the microchip, a green fluorescent protein expressing plasmid, pRSET/EmGFP
(Invitrogen, V353-20), was transferred into the competent E. coli strain BL21 StarTM
(Invitrogen, C6000-03). According to the manufacturer’s instructions, the pRSET/
EmGFP plasmid, which confers ampicillin resistance, was incubated at 42uC for 30
seconds with the competent cells. Cells were allowed to cool down on ice for
2 minutes. 250 mL of Super Optimal broth with catabolite repression medium
(Sigma-Aldrich, S1797) was added to be incubated for an hour at 37uC, while shaking
at 250 rpm. Subsequently, the genetically modified bacteria were spread onto Luria
Bertani (LB) agar plates, which contained 100 mg/mL of ampicillin. The plates were
incubated at 37uC for 16 hours, and cells were allowed to grow. When colonies
appeared, an individually isolated colony was inoculated in a 30 mL of LB broth,
containing 100 mg/mL ampicillin. Then, E. coli culture was incubated for 16 hours in
a 250 rpm rotating incubator at 37uC and aliquoted for later use as a standard stock.
The E. coli stock concentration was quantified by diluting the stock solution nine-
fold in PBS and spreading the dilution onto LB-ampicillin plates to be incubated at
37uC overnight. Finally, individual E. coli colonies were counted, and the concen-
tration of the stock solution was calculated as 109 CFUs/mL. By diluting the stock
concentration into PBS, the concentrations in the experiments were obtained.
For peritoneal dialysis (PD) fluid experiments, E. coli was spiked in a commercial
dialysate, received from Chronic Ambulatory Peritoneal Dialysis (CAPD) Unit from
Faulkners Hospital (Baxter Inc., 5B9766). Sample concentrations ranging from 105 to
3 3 107 CFUs/mL were prepared by serial dilution in PD fluid.
S. aureus culture and quantification. S. aureus (ATCC #25923, American Type
Culture Collection, Mannassas, VA) cells were hydrated and streaked for isolation on
a Luria Bertani agar (LA) plate. Following growth, a single isolated colony was
selected and inoculated in 3 mL of Luria bertani (LB) media. The bacteria culture was
grown on an incubator shaker for 18 hours at 37uC, 250 rpm until it reached the
stationary phase. Quantification of S. aureus stock concentration was done by
diluting the overnight cultures nine-fold in PBS. Diluted cultures were streaked onto
LB Agar plates, incubated at 37uC overnight and individual S. aureus colonies were
counted after overnight incubation. The concentration of stock cultures was
calculated as 109 CFUs/mL. For validation experiments, the overnight cultures were
diluted at a ratio of 1510 in LB media.
Portable biosensor operating principle and fabrication. The SPR platform was
custom-made formicrofluidic integration (Figure 1a, b). The design of the systemwas
based on Kretschmann configuration, which uses prism coupling to satisfy
momentum conservation for plasmon excitation by an external light source33
(Figure 1c). A collimated point source light emitting diode (LED) output (l 5
705 nm) was focused with a cylindrical lens (f 5 15 mm) and passed through a glass
prism (N-BK7, n 5 1.51) to illuminate the surface of the microchip. The rectangular
prism was positioned on a stage, which was practical for inserting microfluidic chips
and the prism. Reflected light was captured by a CMOS sensor (500 3 582), which
was placed such that the normal of the sensor surface was parallel to the monitored
light direction. The light source, CMOS sensor, and the associated optical and
electrical components were packaged in a portable box with dimensions of 13.5 cm3
10 cm 3 5.2 cm (length 3 width 3 height) (Figure 1a, b). The total weight of the
packaged system was 0.85 kg (1.87 lbs). The disposable microfluidic chips were then
placed on the prism with a thin layer of index matching liquid (n 5 1.5000 6 0.0002,
Series A, Cargille Labs, NJ) and fixed in place (Figure 1a). The index matching liquid
was used for providing lossless optical transmission between the prism and the glass
substrate on the microchip. A custom-designed software was used to monitor the
resonance angle changes. The software captured the image frames from the sensor,
calculated the resonance angle in real time, and then, plotted the resonance curve and
the sensogram (resonance angle as a function of time) as a readout for kinetic
measurements.
Calibration. To calibrate the sensor, fluids (i.e., distilled water PBS and ethanol (200
proof)) with known refractive indices were used as reference samples, and their
plasmon resonance curves were measured in microfluidic channels. Then, the
instrument parameters were matched to these experimental curves to extract device
fitting parameters. In the Kretschmann configuration, the surface plasmon mode’s
wave vector, ksp, is described by ksp~v=c
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
e1e2=(e1ze2)
p
, where v is the angular
frequency of the incoming light, c is the speed of light, e1 and e2 are the dielectric
permittivity of the gold and biosensor medium34. The resonance condition occurs
when the surface plasmon mode wave vector is equal to the incident light’s wave
vector in the plane of the interface, i.e., ksp 5 v/c (n Sinh) where n is the refractive
index of the prism and h is the incidence angle of the light35. The calibration procedure
allowed an active operating range of 67 to 73 degrees for the resonance angle and the
smallest angle shift the device showed sensitivity was 0.002u. All calibration
measurements and validation experiments were performed at room temperature.
Functionalization ofmicrochannels for label-free E. coli and S. aureus capture and
detection. The surface modification for E. coli and S. aureus detection was performed
on the 50 nm gold coated glass wafers. The gold surfaces were first submerged in
acetone bath at 56uC to clean any organic residues from the nanofabrication and chip
dicing. The gold chips were incubated with 10 mM of 11-Mercaptoundecanoicacid
(MUA) (450561 Aldrich – Sigma Aldrich) dissolved in ethanol overnight, and thus,
self-assembled monolayer with carboxyl groups was generated onto the surface. After
MUA modification, microfluidic channels were constructed. Then, a 100 mL of, 151
mixture of 100 mM N- (3 - Dimethylaminopropyl) – N9 -ethylcarbodiimide
Hydrochloride (EDC, 03450 Fluka – Sigma Aldrich) in 10 mLMES (M3671 Sigma –
Sigma Aldrich) buffer (9,76 mg/mL in dH2O) and 50 mM of N-Hydroxysuccinimide
(NHS, 130672 Aldrich – Sigma Aldrich) in 10 mL of MES buffer, was loaded with
pipettes to microchips through the inlet port and incubated for 30 minutes. EDC
reacts with carboxyl groups for the formation of amine reactive intermediate that is
stabilized by the addition of NHS. The final chemical product is a succinimide group
that reacts with amine groups of organic compounds (e.g., proteins). The surfaces
were then washed with 100 mL of distilled water and 300 mL of PBS. This step was
followed by introducing 100 mL of Protein G (0.1 mg/mL) (21193 – Thermo
Scientific) dissolved in PBS for the immobilization of antibodies with their favorable
orientations, and Protein G was incubated at 4uC for an hour. The surfaces were then
washed with 300 mL of PBS. 100 mL of anti-lipopolysaccharide (LPS) antibody
(ab35654 – Abcam) (5 mg/mL) solution in PBS was incubated for 30 minutes, and
thus, antibodies were immobilized on the Protein G coated layer to capture GFP-
expressing E. coli. For S. aureus experiments, 100 mL of anti-lipotheichoic acid (anti-
LTA) antibody (MA1-7401 – Thermo Scientific) (5 mg/mL) solution in PBS was
incubated on Protein G-coated surfaces for 30 minutes. After another wash with
300 mL of PBS, various concentrations of E. coli ranging from 3.2 3 105 to 3.2 3
107 CFUs/mL in PBS were passed through the chip at 5 mL/min rate for detection. In
PD fluid experiments, 105 to 3.2 3 107 CFUs/mL of E. coli spiked in PD fluid were
passed through the chip at 5 mL/min rate for detection. In S. aureus experiments, 5 3
106 CFUs/mL were tested for multiplexing and selectivity of the platform.
Statistical Analysis. To evaluate each SPR angle shift, we facilitated one-way analysis
of variance (ANOVA) with Tukey’s posthoc test followed with Bonferroni’s Multiple
Comparison Test for equal variances for multiple comparisons with statistical
significance threshold set at 0.05 (p , 0.05). Error bars in the plots represented
standard error of the mean (SEM). All statistical analyses was performed using
GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA).
Results and Discussion
E. coli capture and quantification in the microchannels. To capture
E. coli on microfluidic chips, we utilized a Protein G-based surface
chemistry that allows to immobilize antibodies in a favorable
orientation18. It was previously shown that anti-LPS presented
highest capture efficiency among a set of antibodies (antiflagellin,
anti-LPS and CD14) for on-chip E. coli capture when Protein G
based surface chemistry was performed6. We adapted the surface
chemistry for gold-coated substrates, to target E. coli capture on a
microfluidic chip. The captured bacteria counts between the inlet
and outlet ports were evaluated, for chip characterization as well as
for the limit of detection measurements. To quantify the number of
bacteria captured on gold surfaces, a 75 mL of 106 CFUs/mL E. coli
was passed through surface functionalized microchips (Figure 2a) at a
5 mL/minute flow rate using a syringe pump. The GFP-expressing E.
coli was fluorescence imaged under 103 magnification (Figure 2b). To
evaluate the capture specificity, brigthfield images and fluorescence
images at 1003 magnification of the same spot were compared
(Figure 2c, d).
We first addressed two considerations, i.e., autofluorescence and
clustering, which could potentially result in erroneous estimates of
bacterial counts. Autofluorescence may interfere with the samples
under study and could potentially result in erroneous estimates of
bacterial counts. To confirm that the fluorescence spots in the images
were coming from the bacteria (not from autofluorescence of other
particles), we gathered bright field images of 16 locations (99 mm 3
66 mm) on a chip at 1003 magnification and compared the mor-
phology of E. coli observed in these images with green spots observed
in the corresponding fluorescence images under 1003 magnifica-
tion. These images showed no autofluorescence effects (Figure 2c, d).
Additionally, clustering of bacteria could also potentially result in
under-quantifying the bacteria on the sample surface. Therefore, we
required that each observed point with fluorescence under the 103
magnification images should be associated with a single bacteria and
not resulting from the clustering of E. coli. To confirm these observa-
tions, we took a fluorescence image under 103magnification and 25
www.nature.com/scientificreports
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fluorescence images with 1003 magnification uniformly sampling
the 103 image area. Using the twenty-five 1003 images, we esti-
mated a total of 82 E. coli on the imaged surface under 103 mag-
nification. In comparison, 78 fluorescing points were counted in the
103 image. We concluded that clustering did not also play a signifi-
cant role in the 103 image E. coli counts. Therefore, in the consec-
utive capture distribution analysis and limit of detection experiments,
fluorescent images with 103 magnification are utilized for bacterial
counts.
Capture Distribution Experiments. To evaluate the capture
distribution of bacteria, six microchips were tested with 100 mL of
106 CFUs/mL E. coli spiked in PBS. The cell capture distribution
along the microchannels were evaluated by identifying one
longitudinal region passing through the inlet and outlet ports and
three additional regions that are perpendicular to the flow direction
in the microchannel. The captured E. coli were then manually
quantified using fluorescence images taken under 103 magnif-
ication. The longitudinal region passing through the ports and
center of the microchannel was evaluated with 10 images
(0.987 mm 3 0.658 mm) under 103 magnification (Figure 3a).
The evaluated region covered the distance between the inlet and
outlet ports. The maximum capture of E. coli was observed at 2–
3 mm away from the inlet port and was consistent with previous
microfluidic experiments on glass substrates36. The three regions
perpendicular to the flow direction were also evaluated with fluore-
scence images under 103 magnification. One region perpendicular
to the flow and passing through 1 mm to the right of the inlet, a
second one passing through 1 mm to the left of the outlet and a third
one passing through the center of the chip were evaluated with 7
images (0.987 mm 3 0.658 mm) each (Figure 3b, c, and d). The
capture distribution showed a slight peak around the center of
these regions but in general a uniform distribution was observed in
the direction perpendicular to the flow.
SPR angle and kineticmeasurements.The field of view of the sensor
corresponded to an area of 1 cm 3 0.5 cm on the gold chip surface
(Figure S2). The resonance angle was defined as the angle at which
there was maximum light coupling to the plasmon modes37. The
resonance condition was satisfied at angles corresponding to a
band which was observed as a dark shadow on the camera (Figure
S2a). The custom-developed software averaged the pixel intensities
in a selected viewing area and converted the mean intensity as
a function of distance to mean intensity as a function of the
incidence angle. The minimum point of this band was calculated
in real time and the SPR sensogram was generated, allowed the
probing of surface events. A two inlet microchip was prepared for
evaluating the rise time (i.e., time to increase from 10% to 90% of the
resonance angle difference between the water and PBS signals) of the
platform. Distilled water and PBS were alternately applied by syringe
pumps at 5 mL/min flow rate, and the switching of liquids was
evaluated. The rise time of the switching was observed as 8
seconds (Figure S2b, S2c).
For kinetic measurements and the evaluation of surface functio-
nalization protocol, described in the Materials section
(Functionalization of microchannels for label-free E. coli and S. aur-
eus capture and detection section), the microchip surfaces were acti-
vated using syringe pumps at 5 mL/min flow rate, while they were
mounted on the SPR platform. During the washout steps with PBS,
we observed the signal stayed constant. Eachmodification step in the
surface functionalization increased the resonance angle by changing
the refractive index near the gold surface (Figure 4a). Protein G and
anti-LPS binding were observed rapidly as well as other surface
events at the interface (Figure 4a). Subsequently, this protocol was
modified to be applied with pipettes, allowing for multiple microchip
preparation in a parallel manner and used in the E. coli capture and
detection experiments with the SPR platform. A representative res-
onance shift in the SPR curve upon capture and detection of bacteria
is illustrated in Figure 4c.
Figure 2 | Microfluidic chip and fluorescent images of E. coli taken under 103 and 1003magnifications in microchannels. (a) Microfluidic chip and
the geometry of the channel formed by the 50 mm thick double sided adhesive tape. (b) Captured GFP-expressing E. coli on the gold surface was
fluorescently imaged at 103 magnification in the centre of the microchip. 75 mL of 106 CFUs/mL E. coli in PBS was run through the chip. The 103
fluorescence image was taken in the centre of themicrochannel and was used to count the green fluorescing spots to give a count of 78. (c) Captured GFP-
expressing E. coliwas fluorescently imaged at 1003magnification. Bacteria are indicated with white circles. (d) Bright-field image at 1003magnification
shows the morphology of bacteria, indicated with white circles, for the same image shown in (c).
www.nature.com/scientificreports
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Limit of Detection and Standard Curves. In the literature, the limit
of detection (LOD) of an SPR sensor is reported mainly as a function
of the concentration of cells introduced to the system38. This metric
does not take the sample volume into account. Therefore, we
evaluated the LOD using two approaches. In the first approach, a
fixed volume (100 mL) was used, and the lowest detectable bacteria
concentration was evaluated. Standard curves were also provided
for bacteria quantification in PBS solution and in PD fluid. In
comparison, the second approach evaluates the absolute number of
bacteria captured within the active area of the sensor inducing a
detectable resonance shift given a fixed concentration.
To evaluate the response range and potential applicability of the
system to biological systems, we analyzed various concentrations of
E. coli suspensions in PBS. A representative sensogram demonstrat-
ing E. coli detection is shown in Figure 4b. First, PBS was introduced
into the surface functionalized channel, then 100 mL of 106 CFUs/
mL of E. coli was passed at 5 mL/minute, and finally PBS was intro-
duced again to wash unbound bacteria. We observed that the signal
stayed constant during PBS runs, whereas a signal increase was
observed in time when the E. coli was introduced. For the response
curve analysis, E. coli concentrations of 3.2 3 105 CFUs/mL,
106 CFUs/mL, 2 3 106 CFUs/mL, 6.3 3 106 CFUs/mL, 2 3
107 CFUs/mL, and 3.23 107 CFUs/mL spiked in PBSwere evaluated
at 5 mL/minute flow rate (Figure 5). At each concentration, six
microchips were run for 20 minutes to generate reliable signal levels.
The platform demonstrated a linear response (R2 5 0.98) between
the plasmon signal and the logarithm of the E. coli concentration
within the 3.2 3 105–3.2 3 107 CFUs/mL range. We observed plas-
mon shifts of,0.02u and,0.38u at concentrations 3.2 3 105 CFUs/
mL and 3.23 107 CFUs/mL, respectively. The standard curve shown
in Figure 5 can be used to calculate an unknown E. coli concentration
spiked in PBS for quantitative analysis. The LOD for E. coli capture
and detection with direct immunoassays in SPR-based systems is
,106 CFUs/mL39,40. Lower LODs have also been reported, but with
bulky SPR systems that employ sandwich assays to improve the
LOD41. For instance, a flow-cell based SPR sensor was reported to
detect Salmonella typhimurium at 2.53 105 cells/mL and Salmonella
enteritidis at 2.5 3 108 cells/mL with a sandwich assay42. It has been
also noted that sample preparation may influence the signal levels.
For instance, E. coli was detected using a sandwich assay with an
LOD of 104 CFUs/mL when the bacteria was lysed, 105 CFUs/mL
when the bacteria was heat-killed and with 106 CFUs/mL with
untreated E.coli43. The portable microfluidic-based SPR platform
reported here provides a comparable with these different platforms.
Although sandwich assays, sample labeling and modified sample
preparation techniques can improve the reported LOD, these pre-
processes increase the complexity, thus reducing the applicability in
POC settings44. There are existing commercial SPR platforms
reported45–51 (Table S1). For instance, Biacore device is notably
reported to detect 25 CFUs/mL of E. coli, using 25 mL samples, cor-
Figure 3 | Capture distribution of E. coli in microchannels. (a) The plot represents the overall percentage of captured E. coli in the microchannels
through a horizontal stripe passing from the inlet port to the outlet port. The error bars represent the standard error of the mean (n 5 6). The capture
distribution spatially peaks at 2 mm from the inlet port. During each run, 100 mL of 106 CFUs/mL E. coli was passed through the channel.
(b) Three stripes perpendicular to the channel direction were evaluated for capture distribution for the same chips evaluated in (a). The capture
distribution for the stripe passing through the center of the channel is shown. (c) The distribution for the stripe passing close to the inlet port is shown. (d)
The capture distribution for the stripe passing close to the outlet port is shown. The error bars indicate standard error of themean normalized to the total
E. coli count on each chip (n 5 6). Approximately a uniform capture distribution was observed in the direction perpendicular to the flow.
www.nature.com/scientificreports
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responding to an absolute value of 0.62 CFU/mL of E.coli (less than
1 CFU) in the total evaluated sample volume. This performance is
reached at the expense of portability, since the Biacore laboratory
equipment weighing 50 kg is not suitable for POC applications44,52.
In comparison, this work reports a portable device (0.85 kg) suitable
for POC applications, with a favorable LOD in comparison to the
mean of the values given in Table S1. The platform reported here
requires lower sample volume, as well as provides significant advan-
tages using disposable chips and portable reader for POC applications.
As an example of a biologically relevant fluid, we evaluated the
detection of E. coli samples spiked in PD fluid at the concentration
range of 105 CFUs/mL to 3.2 3 107 CFUs/mL (Figure 6). The plat-
form performed well in comparison to the PBS experiments, with an
R2 value of 0.98 for the linear fit. At the highest concentration of 3.23
107 CFUs/mL we observed a signal of,0.11 degrees in comparison
to the ,0.38 degrees of PBS experiments given in Figure 5. We
observed the slope of the linear fit was slightly smaller. PBS and
PD fluid have different chemical and optical properties (e.g., refract-
ive index, pH), which may contribute to the resonance angle shifts
observed in experiments at the same E. coli concentrations. During
the PD fluid experiments the experimental parameters (i.e., surface
functionalization, chip design) were kept the same as in the PBS
experiments, however a different batch of gold coated chips were
used, which may also have contributed to the difference in the
observed signal levels.
In the second LOD approach, we evaluated the absolute number of
cells that the system is sensitive to, which was defined as the absolute
LOD. Multiple sample volumes between 20 mL and 100 mL were
evaluated to characterize the experimental detection limitation of
the system. The active area on the gold chip surface (5.3 3
106 mm2) inducing this signal was selected (Figure S2) and fluor-
escence images at 103 magnification were collected after separating
the gold substrates from the microchips. For each chip, nine images
were acquired under 103 magnification, and the GFP-expressing
bacteria were counted inducing the signal. From an engineering
point-of-view, we performed experiments at increasing sample
Figure 4 | Evaluation of the platform. (a) Real time monitoring of the surface chemistry steps with respect to surface plasmon resonance angle
change. The modification of the gold surfaces with crosslinkers is followed by Protein G and antibody immobilization on the surface. The signal remains
constant during the wash-out steps with PBS. (b) Representative detection curve of E. coli. First PBS was introduced into the channel, then 100 mL of
106 CFUs/mL E. coli was passed at 5 mL/minute, and finally PBS was introduced again. (c) Representative plot of plasmon resonance shifts after the
application of E. coli to the biosensing platform. The arrow indicates the plasmonic shift due to the detection of GFP-expressing E. coli, when 106
CFUs/mL E. coliwas applied. Theminimum point of the curves are the surface plasmon resonance angles. (d) Limit of detection evaluation from a 20 mL
sample is shown. Protein G and anti-Lipopolysaccharide (LPS)-based surface chemistry optimized for off-device activation was used to capture and
detect 106 CFUs/mL E. coli in PBS. 20 mL of E. coliwas passed through the channel and,0.002u plasmon shift was observed. The 103 fluorescence images
were used to count the green fluorescing spots, andwe observed E. coli count of 326 1.6 (n5 6, error is given in standard error of themean). The red curve
shows a smoothed sensogram to show the limit of detection signal.
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volumes to evaluate detection limitations. Specifically, 106 CFUs/mL
of E. coli in 20 mL PBS solution were applied to five chips for 4 min-
utes, and the sensor recorded a,0.002u shift in the resonance angle
when chips were run at 5 mL/min (Figure 4d). The,0.002u shift was
found to result from 326 1.6 CFUs/mL of E. coli (n5 5, and error is
given in standard error of the mean). The instrument resolution
(,0.002u) reported in the calibration section is commensurate with
the experimentally measured limitation (,0.002u) at 20 mL (see
Calibration section under Materials and Methods). Further,
106 CFUs/mL of E. coli spiked in 30 mL PBS solution were applied
to three other chips for 6 minutes, and a 0.004u shift response was
observed. Nine images at 103 magnification were used to count the
bacteria, and it was found that the ,0.004u plasmon shift was
induced by 55 6 2.1 CFUs/mL of E. coli captured within the active
area (Figure S3). Here, a higher number of chips were run at increas-
ing volumes, and the system responses were evaluated. We carefully
characterized the platform and chose the most robust and reliable
operating conditions. By considering platform performance and
clinical applicability, 100 mL sample volume was used in our experi-
ments with E. coli. Since themeasured signal levels in Figures 4, 5 and
6 were on the order of 0.1u–0.3u for E. coli, and are two orders of
magnitude higher than the experimental instrument resolution
(,0.002u), the chosen volume of 100 mL regularly provided reliable
and robust conditions. The LOD can potentially be improved by
incorporating on-chip or off-chip microfluidic functional elements
to increase the capture efficiency. A good example of this would be
utilizing the same fluid volume multiple times to increase the cap-
tured bacteria.
Specificity and Multiplexing. The specificity and selectivity of the
proposed platform was evaluated with three sets of experiments. The
first experiment was conducted by eluting E. coli over anti-LTA
antibody-modified microfluidic chips. We observed that E. coli
binding is minimum since anti-LTA antibody is specific for Gram
1 bacteria, which exhibited no affinity to E. coli (Figure 7a). As a
result, there was minimal cross-reactivity (nonspecific binding)
observed against E. coli on anti-LTA antibody-modified surfaces
(Dh 5 0.01u) (Figure 7a). The second experiment was designed by
elution of S. aureus over anti-LTAmodified surface. Figure 7b shows
the typical binding curve of S. aureus on anti-LTA-modified surface,
which yielded 0.057u shift in SPR angle. Further, as a third experiment
(negative control), we examined a mixture of S. aureus and E. coli on
anti-LTA antibody-modified surfaces (Figure 7c). Statistical analysis
demonstrated that there is no significant difference between the results
obtained from S. aureus and mixture cases (n 5 3, p . 0.05)
(Figure 7d). Since E. coli has no significant interactions to the anti-
LTA antibody-modified surface (Figure 7a), the SPR angle shift
originated due to S. aureus binding to the surfaces, confirming
selective capture of S. aureus from the mixture. Additionally, the
SPR angle change in E. coli experiments on the anti-LTA antibody-
modified surfaces were observed to be statistically different than S.
aureus and mixture experiments (n 5 3, p , 0.05). Thus, we
demonstrated the specificity, selectivity and multiplexing capability
of our platform.
The development of POC platforms is crucial both for field-based
diagnostics and personalized medicine applications53,54. However,
requirements for the portability of POC instruments hinder the
transition of these devices to diagnostic and monitoring applications
at the bed-side, primary care and resource-constrained settings. The
presented platform incorporates a hand-held optical reader, which
utilizes disposable microchips adaptable to portable and versatile
POC applications. The system operates with small sample volumes
(100 mL), gives results within 20 minutes, and was made from inex-
pensive equipment. The portability of the device (0.85 kg) allows
simple transportation without compromising sensitivity. Themicro-
chips can be disposed of without raising any contamination issues.
The chip fabrication and surface activation procedures are high
throughput, and the whole process can be automated in the future.
Further, plasmonic-based technologies are label-free and detect the
target directly with less complicated protocols compared to fluor-
escent techniques55. Plasmonics allow detection of ultralow concen-
trations of bioagents24,56,57. Therefore, merging microfluidics with
plasmonic based technologies is enabling new operating modalities.
For instance, recent developments in SPR imaging (SPRi) allowed
high throughput on-chip sensors58 and on-chip immunoassays59.
LSPR based platforms are also merging with microfluidics60. Develop-
ment of such novel plasmonic-based microfluidic sensors will poten-
tially contribute to infectious disease diagnosis and monitoring both at
the POC and primary care settings.
Figure 5 | Validation with E. coli in PBS. The concentrations of 3.2 3
105 CFUs/mL, 106 CFUs/mL, 2 3 106 CFUs/mL, 6.3 3 106 CFUs/mL, 2 3
107 CFUs/mL, and 3.2 3 107 CFUs/mL were evaluated. At each
concentration, 6 microchips were evaluated at 5 mL/minute for
20 minutes. The linear curve shows the least squares fit with R2 5 0.98 (n5
6, error bars represent standard error of the mean).
Figure 6 | Validation with E. coli spiked in peritoneal dialysis (PD) fluid.
The concentration range of 105 CFUs/mL to 3.2 3 107 CFUs/mL was
evaluated. At each concentration, 6 microchips were evaluated at 5 mL/
minute for 20 minutes. The linear curve shows the least squares fit with R2
5 0.98 (n 5 6, error bars represent standard error of the mean).
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Conclusions
We have developed a portable, label-free pathogen detection plat-
form that merged microfluidic and SPR technologies on a single
platform and demonstrated detection and quantification of bacterial
pathogens. Using a plasmonic-based microchip sensitive pathogen
detection is attained, which can potentially be used for POC applica-
tions. We further evaluated the response of the platform with detec-
tion of E. coli-spiked in PBS and PD fluid. The demonstrated system
can potentially be generalized to other pathogens or for immuno-
diagnostics, given that there are well-defined biomarkers for the
targeted applications. For instance, the presented platform is poten-
tially applicable to other bacterial and viral diseases such as influenza,
hepatitis, AIDS, and tuberculosis. Therefore, with the use of dispos-
able, easy-to-fabricate and sensitive plasmonic surfaces with a spe-
cific surface chemistry on a label-free microfluidic platform, we
address some of the major problems of current biosensing tools at
the POC (i.e., portability, cost, small sample size and practical opera-
tion requirements).
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